These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15718336)

  • 1. Thalidomide with continuous low-dose dexamethasone for multiple myeloma.
    Gardyn J
    J Clin Oncol; 2005 Feb; 23(6):1323. PubMed ID: 15718336
    [No Abstract]   [Full Text] [Related]  

  • 2. Ultra low dose thalidomide in myeloma revisited.
    Patrick HE; Bowcock SJ
    Br J Haematol; 2010 Jul; 150(2):232-4. PubMed ID: 20346009
    [No Abstract]   [Full Text] [Related]  

  • 3. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
    Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
    Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.
    Goldschmidt H; Sonneveld P; Cremer FW; van der Holt B; Westveer P; Breitkreutz I; Benner A; Glasmacher A; Schmidt-Wolf IG; Martin H; Hoelzer D; Ho AD; Lokhorst HM; ;
    Ann Hematol; 2003 Oct; 82(10):654-9. PubMed ID: 12845480
    [No Abstract]   [Full Text] [Related]  

  • 5. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
    Richardson P; Anderson K
    J Clin Oncol; 2006 Jan; 24(3):334-6. PubMed ID: 16365174
    [No Abstract]   [Full Text] [Related]  

  • 6. Bisphosphonates may potentiate effects of thalidomide-dexamethasone combination in advanced multiple myeloma.
    Ural AU; Avcu F
    Am J Hematol; 2006 May; 81(5):385-6; author reply 386. PubMed ID: 16628715
    [No Abstract]   [Full Text] [Related]  

  • 7. Ultra low dose thalidomide in elderly patients with myeloma.
    Bowcock SJ; Minchom A; Yates LR; Ryali MM
    Br J Haematol; 2008 Apr; 141(1):120-2. PubMed ID: 18279458
    [No Abstract]   [Full Text] [Related]  

  • 8. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
    Wang M; Weber DM; Delasalle K; Alexanian R
    Am J Hematol; 2005 Jul; 79(3):194-7. PubMed ID: 15981221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combo drug therapy beneficial for new cases of multiple myeloma.
    Health News; 2006 Feb; 12(2):9. PubMed ID: 16456922
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
    Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
    Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
    Sidra G; Williams CD; Russell NH; Zaman S; Myers B; Byrne JL
    Haematologica; 2006 Jun; 91(6):862-3. PubMed ID: 16769594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide and dexamethasone in patients with multiple myeloma not undergoing upfront autologous stem cell transplantation.
    Blade J
    Haematologica; 2005 Dec; 90(12):1589. PubMed ID: 16330426
    [No Abstract]   [Full Text] [Related]  

  • 14. Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report.
    Eo WK; Kim SH; Cheon SH; Lee SH; Jeong JS; Kim YS; Chang HK; Suh KS; Kim HY
    Ann Hematol; 2010 Apr; 89(4):421-2. PubMed ID: 19693501
    [No Abstract]   [Full Text] [Related]  

  • 15. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
    Hassoun H; Reich L; Klimek VM; Dhodapkar M; Cohen A; Kewalramani T; Zimman R; Drake L; Riedel ER; Hedvat CV; Teruya-Feldstein J; Filippa DA; Fleisher M; Nimer SD; Comenzo RL
    Br J Haematol; 2006 Jan; 132(2):155-61. PubMed ID: 16398649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide plus monthly high-dose dexamethasone in chemorefractory myeloma. Results of a phase II clinical study.
    Bernardeschi P; Giustarini G; Montenora I; Turrisi G; Dentico P; Rossi S; Turano E; Fiorentini G
    In Vivo; 2006; 20(6A):719-20. PubMed ID: 17203753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
    Kyriakou C; Thomson K; D'Sa S; Flory A; Hanslip J; Goldstone AH; Yong KL
    Br J Haematol; 2005 Jun; 129(6):763-70. PubMed ID: 15953002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
    Rajkumar SV; Blood E; Vesole D; Fonseca R; Greipp PR;
    J Clin Oncol; 2006 Jan; 24(3):431-6. PubMed ID: 16365178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Chim CS
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.